Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.

Citation for published version (APA):

DOI:
10.1016/j.ejca.2004.01.020

Document status and date:
Published: 01/01/2004

Document Version:
Publisher’s PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.tue.nl/taverne

Take down policy
If you believe that this document breaches copyright please contact us at:
openaccess@tue.nl
providing details and we will investigate your claim.
Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice

Q.G. de Lussanet\textsuperscript{a,b}, R.G.H. Beets-Tana\textsuperscript{a}, W.H. Backesa\textsuperscript{a}, D.W.J. van der Schaft\textsuperscript{c,d}, J.M.A. van Engelshoven\textsuperscript{a,b}, K.H. Mayoe\textsuperscript{c}, A.W. Griffioen\textsuperscript{c,d,*}

\textsuperscript{a}Department of Radiology, Maastricht University Hospital, Maastricht, The Netherlands
\textsuperscript{b}Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands
\textsuperscript{c}Angiogenesis Laboratory, Department of Internal Medicine and Department of Pathology, Maastricht University Hospital, Maastricht, The Netherlands
\textsuperscript{d}Research Institute for Growth and Development (GROW), Maastricht University Hospital, Maastricht, The Netherlands
\textsuperscript{e}Department of Biochemistry, University of Minnesota Health Sciences Center, Minneapolis, MN, USA

Received 5 June 2003; received in revised form 12 January 2004; accepted 15 January 2004

Abstract

The purpose of this study was to evaluate the effects of anginex on tumour angiogenesis assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine. C57BL/6 mice carrying B16F10 melanomas were treated with anginex, TNP-470 or saline. Tumour growth curves and microvessel density (MVD) were recorded to establish the effects of treatment. DCE-MRI was performed on day 16 after tumour inoculation, and the endothelial transfer coefficients of the microvessel permeability surface-area product (KPS) were calculated using a two-compartment model. Both anginex and TNP-470 resulted in smaller tumour volumes ($P<0.0001$) and lower MVD ($P<0.05$) compared to saline. Treatment with anginex resulted in a 64% reduction ($P<0.01$) of tumour KPS and TNP-470 resulted in a 44% reduction ($P=0.17$), compared to saline. DCE-MRI with a clinically available, small-molecular contrast agent can therefore be used to evaluate the angiostatic effects of anginex and TNP-470 on tumour angiogenesis.

Keywords: Angiogenesis inhibitors; Angiostatic agents; Anginex; B16 melanoma; Gd-DTPA; Gadopentetate dimeglumine; Mice; Microvascular permeability; MRI; MRI, functional; TNP-470

1. Introduction

Angiogenesis is essential to normal bodily processes such as embryogenesis and wound healing, but it is also a key regulator of various pathological disorders, including tumour growth, arthritis, endometriosis, atherosclerosis and diabetic retinopathy \cite{1,2}. The targeting of blood vessels is considered a potentially useful anticancer strategy, primarily because endothelial cells are more accessible than other cells to pharmacological agents delivered via the blood, and because they are genetically stable and thus not easily mutated into drug-resistant variants. Anti-angiogenesis therapy could be a promising modality in the future, either as monotherapy or in combination with conventional cancer therapy \cite{1}. The search for new inhibitors of angiogenesis with reduced toxicity, improved potency, stability, selectivity and ease of delivery is an important field of research. A revolutionary development in this search has been the design of small, cytokine-like peptides that contain only selective domains of traditional anti-angiogenesis agents in order to create well-defined antitumour agents that focus on specific angiogenesis processes. This approach produced anginex, which was designed...
according to the three-dimensional, β-sheet structure of α-chemokines such as platelet factor 4 and interleukin 8 [3].

In vitro anginex acts by blocking the adhesion and migration of activated endothelial cells [3], leading to cell detachment, a process that is called anoikis, and the subsequent induction of apoptosis. In vivo anginex targets angiogenically activated (tumour) endothelial cells and inhibits angiogenesis, ultimately leading to anticancer activity in mice, both as a single therapy and in combination with chemotherapy [4], with no toxic effects observed thus far [5].

Generally accepted standards of reference for evaluating angiogenesis activity and the effects of treatment are the histological assessment of microvessel density (MVD) and the measurement of circulating angiogenesis factors. The reliability of these surrogate markers is subject to considerable dispute. New techniques for monitoring the effects of anti-angiogenesis treatment that are less or non-invasive are currently under investigation [6]. Dynamic contrast-enhanced, T₁-weighted magnetic resonance imaging (DCE-MRI) [6–9] is a non-invasive imaging technique that can be used to derive microcirculation properties that mark tumour angiogenesis [7,10]. Various models have been investigated that relate changes in signal intensity over time as measured with DCE-MRI to tumour activity. The most effective models are those that convert the measured changes in signal intensity into changes in contrast-agent concentration and subsequently apply a pharmacokinetic two-compartment analysis. Two-compartment analysis yields parameters for a plasma fraction (fPV) within the tumour and a rate of exchange between the blood and interstitial compartments (i.e. a transfer coefficient, Kps) [8]. Applications of DCE-MRI in animal MR systems and with experimental, large-molecular contrast agents effectively showed reductions in fPV and Kps in the rim of solid tumours after treatment with anti-angiogenesis agents [8] including the fumagillin derivative TNP-470 [10]. Currently, such large-molecular contrast agents are unsuitable for DCE-MRI in man. Preliminary evidence suggests that DCE-MRI studies are reproducible when using clinical 1.5 Tesla MR systems and clinically approved, small-molecular contrast agents [11,12].

It was hypothesised that the anti-angiogenesis mechanism of anginex will lead to a decreased tumour MVD and to maturation of the vasculature, which would be expected to reduce the tumour transfer coefficient. The aim now was therefore to evaluate the anti-angiogenesis effects of the angiostatic compounds anginex and TNP-470 on tumour angiogenesis assessed by DCE-MRI on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine.

2. Materials and methods

2.1. Mouse tumour model

The local ethical review committee approved the animal experiments. B16F10 melanoma cells (provided by Dr J. Fidler, Texas) were cultured in minimal essential medium (MEM) with Hank’s salts, 10% fetal calf serum (BioWhittaker, Verviers, Belgium), 50 IU/ml penicillin (ICN, Aurora, Ohio) and 50 IU/ml streptomycin (Seva, Heidelberg, Germany), MEM vitamins, 2-mM l-glutamine, non-essential amino acids and 2 mM sodium pyruvate. Cells were harvested with trypsin (0.125%) (DIFCO, Detroit, Michigan). At day 0, 6-week-old C57BL/6 mice (n = 34) (obtained from Charles River, Heidelberg, Germany) were inoculated subcutaneously in the right flank with 2×10⁵ B16F10 cells. Once tumours became visible, between day 6 and 9, each one was measured daily with a calliper and tumour volumes were recorded, calculated as width²×length×0.52 [13]. Mice were randomised and treated with anginex (n = 14), the established angiogenesis inhibitor TNP-470 (n = 9) or saline (0.9% NaCl solution) alone (n = 11), using previously optimised drug dosages and modes of administration [3,14]. Anginex [3], dissolved in saline, was administered (6 mg/kg body wt per day) from day 0 through a surgically implanted Alzet osmotic minipump (Durect, Cupertino, CA). TNP-470 (provided by Takeda Chemical Industries, Osaka, Japan), dissolved in saline with 3% ethanol and 5% glucose (just before treatment diluted from a stock of 30 mg/ml in dimethyl sulphoxide), was administered by intraperitoneal injection (60 mg/kg body wt) every other day. Treatment with TNP-470 was started from day 9 to allow the formation of an early-stage tumour and prevent toxic effects due to prolonged treatment.

2.2. MRI

On day 16, 13 mice from the population described above, with volume-matched tumours to exclude tumour size-dependent differences [10], were selected for MRI (saline, n = 5; anginex, n = 5; TNP-470, n = 3). Before imaging the mice were anaesthetised by subcutaneous injection of 100 mg/kg body wt ketamine (Nimatek; Eurovet, Bladel, The Netherlands) and 10 mg/kg xylazine (Sedamun; Eurovet), and the subcutaneous osmotic minipumps were removed. MRI was as previously reported [12], using a circular surface coil (5 cm dia.) and a 1.5 Tesla system (Intera; Philips, Best, The Netherlands). A T₂-weighted acquisition [multislice turbo-spin echo, echo-train length 28, repetition time (TR) 3.3 s, echo time (TE) 200 ms, flip angle (FA) 90°] that covered the tail-end half of the mouse was used for tumour delineation, with 16 transverse sections, a field of view of 44×64×32 mm (anterior-posterior×left-right×feet-head).
matrix dimensions of 88×128, pixel size 0.5×0.5, and slice thickness 2.0 mm. Six T1-weighted acquisitions [three-dimensional fast-field echo (3D FFE), TR 50 ms, TE 7 ms] were performed with different FA (2°, 5°, 10°, 15°, 25° and 35°) to determine the local T1-relaxation times before contrast enhancement [15]. Subsequently, a T1-weighted, dynamic contrast-enhanced series of 50 scans (3D FFE: TR 50 ms, TE 7 ms, FA 35°), 39 s/volume acquisition) was conducted, with 16 transverse sections, a field of view of 44×64×32 mm, matrix dimensions of 88×128, a slice thickness of 4.0 mm, and pixel size 0.5×0.5 mm. Adjacent sampled sections were 2.0 mm displaced and subsequently interpolated to 16 2.0 mm-thick sections during reconstruction. Gadopentetate dimeglumine (Magnevist; Schering AG, Berlin, Germany; 0.1 mmol/kg body wt) was manually infused into the tail vein with 15 μl of saline to ‘flush’ the injected volume. Administration of the total injection volume was standardised by timing the (slow) injection duration of 30 s to prevent the high concentrations that might cause susceptibility artefacts. Injection of contrast agent was started at the onset of the fifth scan of the dynamic series. The temperature in the magnet bore was maintained at 28 °C.

2.3. Analysis of MRI data

The T2-weighted anatomical acquisitions were used to locate and delineate the tumour from the surrounding tissue and oedema. A region of interest was manually drawn around the whole tumour volume in the central slice though the tumour. This region of interest was used for further analysis. Regions of interest for the tumour rim were defined as the approximately 1 to 2 mm-thick peripheral zone of strong contrast enhancement [7] in the dynamic T1-weighted series; the tumour core was the remaining central region.

Kinetic analysis of the images was performed as described previously [12]. Local time-averaged T1 relaxation rates of the precontrast images (R10) and the postcontrast image (R1) signal-intensity changes over time (Fig. 1) were used to determine the time course of the plasma concentration in the aorta, representing the arterial input function and tissue concentration in the tumour. Individual input functions were used to correct for small variations in the manual injection of the contrast agent, intrinsic circulation properties and contrast elimination. The plasma R1(t) time course was fitted to a bi-exponential function. The constant (i.e. T1 relaxivity) describing the ratio of R1 change to contrast-agent concentration has been found [12] to be 5.6 mM−1 per s by in vitro measurements of mouse plasma (with citrate buffer) concentrations at 1.5 Tesla. A pharmacokinetic, two-compartment, bidirectional exchange model [12,16,17] was used to determine the tumour endothelial transfer coefficient (KPS), reflux coefficient (k) and fractional plasma volume (fPV) for each voxel. KPS and k were expressed as ml/min per 100 cm3 of tissue and fPV were expressed as ml/100 cm3 of tissue. It was previously shown (12) that for this model, using gadopentetate dimeglumine, the KPS is of main interest for indexing angiogenesis activity. Colour-coded KPS maps, overlaid on the corresponding T1-weighted image (as illustrated in Fig. 2), were used for defining regions of interest for which KPS, fPV and k were spatially averaged for the whole tumour, the tumour rim and the core. The data processing was performed in the MATLAB programming environment (The MathWorks, Natick, MA).

2.4. MVD

On day 16, all mice were killed by cervical dislocation under narcosis and tumours were excised. From these tumours, axial cryosections (5 μm) corresponding to the MRI sections were cut and stained immunohistochemically using anti-CD31 antibody (followed by goat anti-rat PO and DAB development). MVD was evaluated as described previously [18]. In brief, two independent observers assessed MVD by counting the number of vessels in three high-power fields randomly selected within a section. In addition, MVD maps were generated for the tumours of mice that underwent DCE-MRI by counting blood vessels in microscopic fields of 0.45×0.45 mm2 (magnification 250×) for a full tumour section.
2.5. Statistical analysis

Tumour growth curves for the anginex, TNP-470 and saline treatment groups were compared by two-way analysis of variance. MVD, KPS, k, and fPV for the different treatment groups, and rim and core MVD in the MVD maps, were compared by unpaired, two-sided Student t-tests. Intratumour rim and core KPS, k and fPV were compared for the treatment and control groups by paired, two-sided Student t-tests. KPS, k, and fPV for the different treatment groups were also evaluated using the Mann-Whitney test to account for possible non-normal distribution of variables. Statistical analyses used commercial software (SPSS 10.0.5; SPSS Inc., Chicago, IL) and the level of significance was set at P < 0.05.

3. Results

3.1. Antitumour activity of TNP-470 and anginex

Anginex inhibited tumour growth by 68% (P < 0.0001), as compared to growth in saline control mice (Fig. 3A). TNP-470 showed 65% inhibition (P < 0.0001) of tumour growth, as compared to saline control mice (Fig. 3A). Tumour MVD was reduced by approximately 50% for both anginex and TNP-470 (P < 0.05; Fig. 3B). Toxic effects were observed after TNP-470 treatment, but not after anginex (data not shown).

3.2. KPS for tumour vessels by MRI in mice treated with anginex

Clear tumour delineation and differentiation from adjacent muscle tissue and oedema was possible with the T2-weighted acquisition (Fig. 2A). KPS in tumours, calculated using T1-weighted DCE-MRI measurements, showed a decrease of 64% (P < 0.01) in anginex-treated mice as compared with KPS in tumours of saline control mice (Table 1). Reductions in KPS were most statistically significant in the rim of the tumour (66%, P < 0.003). The tumour core showed a 67% reduction in KPS, which almost reached statistical significance (P = 0.05; Table 1). MRI on tumours in mice treated with TNP-470 showed decreases in KPS in the whole tumour of 44% (P = 0.17), in the rim of 43% (P = 0.16) and in the core of 43% (P = 0.16) (Table 1). No significant differences

Fig. 2. Transfer coefficient (KPS) and microvessel density (MVD) maps in a control mouse. (A) On the axial T2-weighted image of the mouse, tumour (t) tissue (grey) and oedema (white) are clearly discernible from adjacent muscle tissue (nearly black) of the hind leg (l), within the grey dotted box; d, dorsal side; g, gut. (B) Maps of KPS (ml/min per 100 cm³ of tissue), in pseudo-colour (scale on the right) are superimposed on the T1-weighted image. Areas of low KPS correspond to darker areas in the tumour on the T2-weighted image and were identified as necrotic regions on histological sections of the tumour in the same axial orientation as the MRI slices. (C) Maps of the MVD (vessels/0.2 mm²) of the CD-31-stained histological section show a higher mean MVD for the tumour rim (red, MVD = 5.2 ± 2.6 (SD)) compared to the core (black, MVD = 3.8 ± 1.9), as well as necrotic regions (grey fields).

Fig. 3. Inhibition of tumour growth in mice by anginex and TNP-470. (A) Tumour growth curves show significant inhibition for mice treated with anginex (○, started at day 0; P < 0.0001) and TNP-470 (▲, started at day 9; P < 0.0001) in comparison with saline (■). For clarity, variations in tumour measurements (the SEM was typically 20% in all groups) are only shown for the anginex and the saline groups. (B) Microvessel density (MVD) for tumours of mice treated with anginex, TNP-470 or saline alone (P < 0.05). (C) Transfer coefficient (KPS, ml/min per 100 cm³ of tissue) values (±SEM) measured in the rim of the tumour, showing similar reductions to those from the MVD measurements (P < 0.003).
(P > 0.5) were observed between the KPS of mice treated with anginex or TNP-470.

For the tumours in mice that were selected for DCE-MRI, MVD measurements were performed for the full area of the axial cryosections through the centre of the tumour in correspondence to the MRI sections. MVD maps (Fig. 2C) were aligned and compared with their respective KPS maps shown in pseudo-colour (Fig. 2B). A close similarity was observed between MVD and KPS for individual tumours, of which an example from a saline control mouse is presented in Fig. 2. In addition, MVD maps of the saline control tumours show higher values in the rim of the tumour (36% higher, P < 0.002) than in the tumour core. This difference was only statistically significant in saline control mice; in anginex-treated mice the difference was non-significantly (P > 0.01) or TNP-470- (P > 0.7) treated mice.

### 4. Discussion

The results of this study demonstrate that effects of the angiostatic compounds anginex and TNP-470 on tumour angiogenesis can be assessed by DCE-MRI on a clinical 1.5 Tesla MR system and with the clinically available contrast agent gadopentetate dimeglumine. The novel cytokine-like peptide anginex and the established angiogenesis inhibitor TNP-470 were used to treat cancer in a mouse solid tumour model. TNP-470 is a validated angiogenesis inhibitor and was used here as a positive control according to a previously optimised treatment regimen [14]. Both anginex and TNP-470 are examples of angiogenesis inhibition through direct action on endothelial cells, which has been shown as yet to be the most effective strategy for angiogenesis inhibition as a treatment for cancer [1,4].

In animal studies, the angiostatic effects of compounds are generally assessed by measuring MVD or by detecting circulating angiogenesis factors. MVD is a controversial measure for prognosis because (i) it is a non-physiological variable that cannot differentiate functional from non-functional and non-perfused blood vessels, and (ii) it is subject to considerable (inter- and intra-observer) variation. The latter variability made an international methodological consensus for the assessment of MVD necessary [19]. The detection of circulating angiogenesis factors may similarly suffer from excessive variations, but its major limitation is that it is not yet known what responses (increases or decreases) to expect from specific inhibitors. These considerations necessitate the search for other, preferably non-invasive, surrogate markers. Therefore, great attention is directed toward the development of functional imaging techniques, such as positron-emission tomography, computed tomography, MRI and other non-invasive imaging methods [6], which may localise sites of angiogenesis and offer functional data in animal angiogenesis models and in man. The successful use of MRI has been demonstrated in this study.

More importantly, a clinical MR system and a widely available, clinical small-molecular MR contrast agent proved to be applicable for monitoring the effects of anti-angiogenesis agents and to differentiate the amount of angiogenesis activity within a tumour. Our finding of reduced transfer coefficients after treatment with TNP-470, measured at 1.5 Tesla and with a small-molecular contrast agent, is in line with earlier reported [10] reductions in vascularity and permeability measured in another mouse tumour model with a dedicated, high-field, animal MR system and a large-molecular, experimental contrast agent.
It is important to consider the molecular size of the contrast agent used. First, small- and large-molecular contrast agents may differ greatly in their respective blood concentration changes over time, which may have implications for the required acquisition times and the speed of contrast-agent injection in the dynamic contrast-enhanced series. Blood concentration changes can be expected to be rather larger for small-molecular clinical contrast agents, such as gadopentetate dimeglumine, which are rapidly cleared from the circulation, than for large-molecular experimental contrast agents, which have relatively slow clearance rates. To date, however, no large-molecular contrast agent that is suitable for DCE-MRI has reached approval for clinical use. Good but not perfect correlations were shown between MVD and $K_{PS}$ using the gadopentetate dimeglumine contrast agent in a mouse solid tumour model [12]. Based on that study, as well as the results of our dynamic contrast-enhanced measurements (Fig. 1), we assume our temporal resolution to be sufficient for deriving reliable $K_{PS}$. As is shown in Fig. 1, with a temporal scan resolution of 39 s and a relatively slow speed of injection, sufficient samples were obtained in the rising part of the tissue signal-intensity curve and the declining part of the vascular-input function.

A second reason for regarding the molecular size of the contrast agent used is to explore which physiological properties are reflected by the $K_{PS}$. For small-molecular contrast agents the $K_{PS}$ represents the permeability surface-area product (PS) that is to some extent contaminated by flow, as has been shown in a rat tumour model [20]. Both permeability and flow are suitable microcirculatory properties for characterising the status of tumour vascularisation and are likely to decrease during vascular normalisation. Reductions in $K_{PS}$ after treatment with anginex and TNP-470, which were well correlated with reductions in MVD, could have resulted from reduced microvessel permeability, reduced microvessel surface area (per volume of tissue), reduced blood flow, or a combination of these [8]. A study [21] using a rat breast cancer model showed significant reductions in $K_{PS}$ with the use of large-molecular contrast agents after anti-angiogenesis treatment with anti-vascular endothelial growth factor (VEGF) antibody, but failed to measure these reductions in $K_{PS}$ with the use of small-molecular contrast agents. The anti-angiogenesis effects of anti-VEGF antibody primarily target the initiation of angiogenesis, which involves the induction of microvessel permeability by VEGF [1,2], whereas TNP-470 and anginex directly target endothelial cells involved in new vessel formation [1–5,14]. Therefore, the success of using small-molecular agents to measure the effects of anti-angiogenesis treatment might depend on their biological effects. Other reasons might lie in the details of the applied MRI protocol. For example, we feel that, to monitor the concentration changes, a low rate of contrast-agent injection, rather than high-speed bolus injection (as used in other studies [21]), is essential for rapidly diffusing, small contrast-agent molecules.

The finding that anti-angiogenesis compounds eliminated the rim-core difference in $K_{PS}$ supports the suggestion that treatment with angiostatic compounds can normalise the angiogenesis phenotype of the tumour blood vessels, since angiogenesis is generally most prominent in the rim of a tumour [1,2]. Variations in $f_{PV}$ were too great to reflect significant reductions in blood volume, which may have resulted from the fast diffusion properties of the small-molecular contrast agent. The diagnostic value of the $f_{PV}$ might be better with the future development of large-molecular contrast agents that are safe for injection in man.

The diagnostic value of the reflux parameter (k), derived from the two-compartment model, needs further assessment. Reflux k is commonly set to zero in DCE-MRI studies that use large- molecular contrast agents [7,16]. In our study, k was calculated, but no conclusions were drawn that pertained to differences between treatment groups or differences within a tumour.

Technological advances might optimise DCE-MRI: for example, the development of dedicated MR receiver coils [11] that facilitate faster temporal resolutions and/or increase image quality to further improve $K_{PS}$ and $f_{PV}$ measurements. The rationale for seeking further to improve DCE-MRI using clinical MR systems and clinical contrast agents is ultimately to create a functional imaging tool that may be used in standard oncological MRI protocols. DCE-MRI could be of additional value because its functional parameters might objectify the effects of anti-angiogenesis treatment, possibly even before longer time-scale morphological changes, such as reduction in tumour size, become apparent. DCE-MRI might prove a valuable tool for tumour detection, delineation and staging, as well as for differentiating active regions from non-active or necrotic regions within a tumour, and for the optimisation of individual anti-tumour treatments. Advances in the areas of MRI contrast agents, pharmacokinetic models, imaging techniques and MRI systems, as well as developments in cancer treatments, are continuing. Our preliminary results suggest that DCE-MRI with a clinical 1.5 Tesla MR system and a widely available, small-molecular contrast agent may be used to evaluate the effects of angiostatic compounds on tumour angiogenesis in an animal solid tumour model.

A limitation of this study is that the measured inhibition of tumour angiogenesis using DCE-MRI in this melanoma tumour mouse model after treatment with anginex and TNP-470 may not predict the effects of other anti-cancer treatments in different tumour models. Nor do our results predict $K_{PS}$ or $f_{PV}$ after treating human tumours with either anginex or TNP-470. Further work will be needed using optimised protocols for
human participants to evaluate whether DCE-MRI can indeed successfully demonstrate the effects of angiogenesis treatment in patients with solid tumours.

Acknowledgements

This work was supported by research grants from the National Institutes of Health (CA-96090), the U.S. Department of Defence (Army) (DA/DAMD17-99-1-9564), the Dutch Cancer Society (UM 2001-2529) and ActiPep Biotechnology, Inc. We are grateful to Denisha Walek of the Microchemical Facility of the University of Minnesota, for expertise in the synthesis of peptides.

References